Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Fineline Cube Mar 31, 2026
Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Fineline Cube Mar 31, 2026
Company Drug

Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial

Fineline Cube Jun 16, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...

Drug

Suzhou Zelgen’s JAK Inhibitor Jacktinib Gets NMPA Green Light for COVID-19 Trial

Fineline Cube Jun 16, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval...

Company Drug

Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials

Fineline Cube Jun 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...

Company Deals

WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China

Fineline Cube Jun 16, 2022

China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered...

Company Deals

WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development

Fineline Cube Jun 16, 2022

WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...

Company Drug

Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial

Fineline Cube Jun 16, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...

Company Drug

Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Jun 16, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...

Company Deals

Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution

Fineline Cube Jun 16, 2022

China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare)...

Company Drug

Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review

Fineline Cube Jun 16, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...

Company Deals

MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs

Fineline Cube Jun 16, 2022

Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...

Policy / Regulatory

China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks

Fineline Cube Jun 16, 2022

China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines”...

Company Deals

Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China

Fineline Cube Jun 16, 2022

US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement...

Legal / IP Policy / Regulatory

US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms

Fineline Cube Jun 16, 2022

US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052

Fineline Cube Jun 15, 2022

China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...

Company Drug

Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends

Fineline Cube Jun 15, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...

Company Drug

Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP

Fineline Cube Jun 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...

Company Legal / IP

WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake

Fineline Cube Jun 15, 2022

China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...

Company Drug

Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment

Fineline Cube Jun 15, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...

Company Drug

Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment

Fineline Cube Jun 15, 2022

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...

Company Deals

China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies

Fineline Cube Jun 15, 2022

China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...

Posts pagination

1 … 639 640 641 … 643

Recent updates

  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
  • Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
  • NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
  • Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.